<!DOCTYPE html><html><head><link href='https://fonts.googleapis.com/css?family=Spectral' rel='stylesheet'><style>body {    font-family: 'Spectral';font-size: 14px;}</style></head><body><b>Search Term: </b>(sarcopenia OR osteoarthritis) AND ("gene therapy" OR "genome editing" OR "mRNA therapy")<br><b>Date run: </b>2020/01/02<br><br><h2>PubMed Articles</h2> <br><br><b><a href="https://ncbi.nlm.nih.gov/pubmed/31492821">International Union of Basic and Clinical Pharmacology. CVII. Structure and Pharmacology of the Apelin Receptor with a Recommendation that Elabela/Toddler Is a Second Endogenous Peptide Ligand.</a></b><br><b>Journal:</b> Pharmacol. Rev.<br><b>Two-year IF:</b> 19.51<br><br><b><a href="https://ncbi.nlm.nih.gov/pubmed/31862013">Recommendations for the collection and use of multiplexed functional data for clinical variant interpretation.</a></b><br><b>Journal:</b> Genome Med<br><b>Two-year IF:</b> 10.47<br><br><b><a href="https://ncbi.nlm.nih.gov/pubmed/31694725">34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1 : National Harbor, MD, USA. 6-10 November 2019.</a></b><br><b>Journal:</b> J Immunother Cancer<br><b>Two-year IF:</b> 8.66<br><br><b><a href="http://google.com">More Results...</a></b><br><br><h2>Companies</h2> <br><br><b><a href="https://www.linkedin.com/company/medrego/">Medrego</a></b><br><br><b><a href="http://google.com">More Results...</a></b><br><br><h2>Patents</h2> <br><br><b><a href="http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=1&p=1&f=G&l=50&d=PTXT&S1=((sarcopenia+OR+osteoarthritis)+AND+((%22gene+therapy%22+OR+%22genome+editing%22)+OR+%22mRNA+therapy%22))&OS=+(sarcopenia+OR+osteoarthritis)+AND+("gene+therapy"+OR+"genome+editing"+OR+"mRNA+therapy")&RS=((sarcopenia+OR+osteoarthritis)+AND+(("gene+therapy"+OR+"genome+editing")+OR+"mRNA+therapy"))">Oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders</a></b><br><b>Patent date:</b> December 31, 2019<br><br><b><a href="http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=2&p=1&f=G&l=50&d=PTXT&S1=((sarcopenia+OR+osteoarthritis)+AND+((%22gene+therapy%22+OR+%22genome+editing%22)+OR+%22mRNA+therapy%22))&OS=+(sarcopenia+OR+osteoarthritis)+AND+("gene+therapy"+OR+"genome+editing"+OR+"mRNA+therapy")&RS=((sarcopenia+OR+osteoarthritis)+AND+(("gene+therapy"+OR+"genome+editing")+OR+"mRNA+therapy"))">Fabs-in-tandem immunoglobulin and uses thereof</a></b><br><b>Patent date:</b> December 31, 2019<br><br><b><a href="http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=3&p=1&f=G&l=50&d=PTXT&S1=((sarcopenia+OR+osteoarthritis)+AND+((%22gene+therapy%22+OR+%22genome+editing%22)+OR+%22mRNA+therapy%22))&OS=+(sarcopenia+OR+osteoarthritis)+AND+("gene+therapy"+OR+"genome+editing"+OR+"mRNA+therapy")&RS=((sarcopenia+OR+osteoarthritis)+AND+(("gene+therapy"+OR+"genome+editing")+OR+"mRNA+therapy"))">Antibodies which bind insulin-like growth factor receptor-1 (IGF1R) and methods of use thereof to treat cancer</a></b><br><b>Patent date:</b> December 31, 2019<br><br><b><a href="http://google.com">More Results...</a></b><br><br><br><b><a href="http://google.com">Link to Full Search Results</a></b><br><body><html>